This #PrideMonth, AASLD celebrates the voices of members who are helping advance a more inclusive future for #hepatology and patient care. @RashmeePatilMD reflects on why creating affirming, welcoming clinical environments is essential to building trust and improving care for LGBTQ patients.

For the first time, The Liver Meeting is opening its doors to frontline clinicians including primary care, internal medicine, emergency medicine, and advanced practice. Liver Care for Frontline Clinicians is a one-day program taking place Nov. 7, offering up to 7.0 AMA PRA Category 1 Credits and a practical, case-based program designed to fit liver health into the workflows you already have. Learn more and register for this program here: bit.ly/3RySMXr (Please note: Registration for this program is separate from The Liver Meeting registration and pricing.) #TLM26 #LiverMeeting #FrontlineClinicians #PrimaryCare #MASLD

📢 Call for public comment now open: #AASLD @AGA_Gastro Guideline on #PrimaryBiliaryCholangitis #PBC This guideline is designed to support individualized treatment decisions by weighing the benefits and harms of available therapies. Your expertise can help strengthen the final guideline. Review the draft and share your feedback by Monday, July 13. 🔗Submit your comments here: bit.ly/4e3ToNs

📣 Reminder: Applications for the #AASLD Women’s Leadership Development Program are open through June 26. Designed for early-career women in #hepatology, this program offers leadership training, mentorship from established leaders, and opportunities to expand your professional network. Take the next step in your leadership journey and apply today: bit.ly/4u8uVM8

As #liverdisease rates continue to rise, the need for earlier detection and coordinated care is more urgent than ever. AASLD’s new Liver Care for Frontline Clinicians program equips primary care and other non-specialty healthcare professionals with practical, evidence-based resources to improve liver disease outcomes. #WorldMASHDay #FattyLiverDay Learn more: bit.ly/4xsX9ni

Invest in your knowledge with AASLD's LiverLearning® Access online activities, webinars, and courses designed to support the diagnosis and management of #MASLD and #MASH. View online offerings, including Fundamentals of Liver Disease MASLD (2026), Met-HBV Diagnosis & Management with MASLD in Patients with Chronic HBV Infection, Unmasking MASH and MASLD, and 2025 #ETC: MASLD, MetALD, and ALD. Start learning today >> bit.ly/4otNHtV

Today is #WorldMASHDay. As the prevalence of #MASH and #MASLD continues to rise worldwide, staying current on the latest research is more important than ever. Explore this #AASLD Publications Collection featuring recent articles in @HEP_Journal, @LTxJournal, and @HepCommJournal that are advancing the understanding, diagnosis, and management of #steatotic #liverdisease. #FattyLiverDay ➡️View the collection here: bit.ly/3vXYuaQ.

Today, we recognize both Global #FattyLiverDay and #WorldMASHDay while embracing the updated #liverdisease nomenclature. AASLD is proud to have helped shape the international consensus that led to the adoption of more accurate, patient-centered terminology. What was once known as #fattyliverdisease is now part of the broader category of steatotic liver disease #SLD, including metabolic dysfunction-associated steatotic liver disease #MASLD, and metabolic dysfunction-associated steatohepatitis #MASH. The updated terminology supports more precise research, diagnosis, and communication in #hepatology. Learn more about the nonmenclature change: aasld.org/new-masld-nomencla…

Tomorrow: Join AASLD and @INASL_Liver for a global webinar on advances in #MASH care. Explore how non-invasive testing, innovative therapies like resmetirom and semaglutide, and cardiometabolic management strategies are shaping patient care. Last chance to register: bit.ly/4vcgzL7

🔥 HOT TOPIC 📗 @HEP_Journal Potentially practice-changing for patients with #MASLD and #type2diabetes, this study found that a #GLP-1 receptor agonist–SGLT-2 inhibitor combination was associated with a lower risk of major adverse liver and cardiovascular outcomes compared with either therapy alone. The study also highlights an innovative use of emulation trial methodology to evaluate potential clinical efficacy in the absence of prospective randomized trials. Read the article here ➡️ bit.ly/4e9OME9

The horror stories in hepatology don't have to be inevitable. They happen when the field stops talking to itself. The Liver Meeting is where the right people get in the same room to keep those conversations going. ‼️ Reminder: #TLM26 dates have shifted to Thursday, Nov. 5 - Monday, Nov. 9 — designed to accommodate attendees observing Diwali. #Hepatology #AASLD

Celebrate 🌈Pride Month and join us at noon EDT today, for a discussion on stigma-free, affirming sexual healthcare and viral hepatitis prevention in MSM and transgender populations. Join today's discussion: bit.ly/3RhJFKp

Only one week left to apply for the 2026 AASLD-EASL Masterclass! If selected, you will gain practical skills in networking, mentoring, and publishing from AASLD and EASL faculty. Submit your application now at bit.ly/3Oe7pOx.

Join tomorrow’s webinar on HBV screening, vaccination, and how monitoring can be incorporated into care for patients using/considering PrEP use. Register and become an expert on HCV elimination and education strategies in MSM and transgender populations. bit.ly/3RhJFKp

AASLD is deeply concerned by the May 29 Executive Order directing a review of U.S. childhood vaccine recommendations, including #hepatitisA and #hepatitisB vaccination policies. Vaccination remains one of the most effective tools for preventing #liverdisease. AASLD strongly supports maintaining evidence-based hepatitis A and hepatitis B vaccination recommendations, which have helped dramatically reduce infections, chronic liver disease, cirrhosis, and liver cancer in the U.S. Protecting children from preventable infectious diseases must remain a national priority. Read our statement: bit.ly/4ckbExT

🎉 Join us in celebrating the #AASLD 2026 Distinguished Award recipients! Learn more about their remarkable contributions and accomplishments in #hepatology: bit.ly/4vzuhrN

Spontaneous HDV suppression is rare, but it is predictable, and that changes how treatment timing gets approached. New data from 1,610 patients identifies the key markers: lower baseline HBsAg, HDV RNA, and ALT, plus male sex and diabetes. Research like this is driving hepatology forward. Join the global community advancing it at #TLM26 this November in Denver. Full study in Hepatology: bit.ly/4nY4qXQ #HepatitisD #HDV #Hepatology #AASLD

Stay ahead during Men’s Health Month by exploring best practices in #MASH and #MASLD for the male patients in your care! Access AASLD’s free course today and support their metabolic health through early detection of steatotic liver disease (SLD). Start now: bit.ly/44CcWn2

Join us for the🌈2026 @AASLDtweets #Pride Webinar:🏳️‍🌈Viral #Hepatitis & Sexual Health in #LGBTQ Communities and Beyond🤗 📅 June 9, Tue 🕛 12:00–1:00 PM EDT ✅ AMA PRA Category 1 Credit🆓 🔗liverlearning.aasld.org/Publ… #LiverTwitter #NoHep #HBV #HCV

🎉 AASLD is excited to announce the 2026 Editorial Fellows for @HEP_Journal and @LTxJournal! The 2026 Editorial Fellows will gain unique, hands-on experience in scholarly publishing and journal editorial leadership while working alongside experienced editors at two of the field’s leading hepatology journals. Learn more: bit.ly/4ocpLgq.